Jupiter Wealth Management LLC Decreases Stake in Johnson & Johnson (NYSE:JNJ)

Jupiter Wealth Management LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 18.0% during the fourth quarter, Holdings Channel reports. The fund owned 19,346 shares of the company’s stock after selling 4,251 shares during the quarter. Johnson & Johnson accounts for 1.4% of Jupiter Wealth Management LLC’s investment portfolio, making the stock its 22nd largest holding. Jupiter Wealth Management LLC’s holdings in Johnson & Johnson were worth $2,798,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of JNJ. MRP Capital Investments LLC raised its holdings in Johnson & Johnson by 4.1% in the fourth quarter. MRP Capital Investments LLC now owns 1,640 shares of the company’s stock valued at $237,000 after acquiring an additional 65 shares in the last quarter. Syverson Strege & Co lifted its position in shares of Johnson & Johnson by 4.9% during the fourth quarter. Syverson Strege & Co now owns 1,394 shares of the company’s stock worth $202,000 after purchasing an additional 65 shares during the last quarter. Werba Rubin Papier Wealth Management grew its stake in Johnson & Johnson by 3.3% in the fourth quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company’s stock worth $301,000 after purchasing an additional 66 shares in the last quarter. Denali Advisors LLC increased its holdings in Johnson & Johnson by 1.3% in the fourth quarter. Denali Advisors LLC now owns 5,128 shares of the company’s stock valued at $742,000 after buying an additional 67 shares during the last quarter. Finally, Sage Mountain Advisors LLC raised its stake in Johnson & Johnson by 0.5% during the fourth quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company’s stock valued at $2,106,000 after buying an additional 67 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity

In related news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ stock opened at $153.12 on Friday. The company has a 50-day simple moving average of $155.24 and a 200 day simple moving average of $153.72. The company has a market capitalization of $368.41 billion, a P/E ratio of 23.02, a PEG ratio of 2.56 and a beta of 0.42. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $21.89 billion during the quarter, compared to analysts’ expectations of $21.65 billion. Sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.40%. The ex-dividend date of this dividend is Tuesday, May 27th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s payout ratio is currently 57.84%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on JNJ shares. Sanford C. Bernstein reiterated a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Barclays decreased their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a report on Thursday, April 17th. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Finally, Bank of America lowered their target price on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, April 10th. Eleven research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.